Fig. 3

Additive and multiplicative interactions of platelet parameters with obesity: sensitivity analyses in men. BMI body mass index, Cases number of lung cancer cases, CI confidence interval, HR hazard ratio, MPV mean platelet volume, p-value p-value for RERI derived with the delta method or p-value from Wald test for the multiplicative interaction term, PLT platelet count, RERI relative excess risk from interaction (additive interaction). Cox proportional hazards models including a cross-classification with obese (additive interaction) or an interaction term with body mass index (BMI) on a continuous scale (multiplicative interaction) for either PLT or MPV in men with the following stratifications, adjustments, and follow-up times: Age—stratified by age at recruitment, with follow-up from recruitment and no adjustment. Smoking—like “Age”, additionally adjusted for smoking status and intensity. Main model—stratified by age at recruitment and region and adjusted for height, recent weight change, smoking status and intensity, alcohol consumption, physical activity, Townsend deprivation index, family history of cancer, time of blood collection, fasting time, diabetes, and use of lipid-lowering drugs, antihypertensive drugs, antiaggregant/anticoagulants, non-steroidal anti-inflammatory drugs, and paracetamol. Follow-up: ≥ 2/8 years—like “Main model”, excluding participants with less than 2 or 8 years of follow-up and lagging the entry date with 2 or 8 years, correspondingly. Smoking: Never / Former / Current—like “Main model”, in groups according to smoking status (retaining the adjustment for smoking intensity and time since quit). Antiaggregant: No / Yes—like “Main model”, in groups according to antiaggregant/anticoagulant use. Groups for cross-classifications (dichotomised to high/low) were defined as follows: BMI ≥ 30 kg/m² (obese) or ≥ median (sex-specific) for PLT (234.0 men; 261.4 women) and MPV (9.17 men; 9.25 women)